MRUS News and Press, Merus N.V. From 04/14/23

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced t...

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in...

2023-04-04 09:28:45 ET Summary Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma. The lead asset may file a BLA soon. Merus N.V. ( MRUS ) is a Dutch developer of antibody therapeutics targeting c...

2023-03-15 12:01:09 ET Merus N.V. ( NASDAQ: MRUS ) added ~7% on Wednesday to reach the highest level since November after announcing that abstracts on its MCLA-158 and MCLA-129 product candidates were selected for presentations at the upcoming AACR Annual Meeting. The ...

The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus (MRUS) Presents At J.P. Morgan Healthcare Conference

Merus press release ( NASDAQ: MRUS ): Q4 GAAP EPS of -$2.92. Revenue of $41.59M (-0.7% Y/Y) misses by $7.51M . For further details see: Merus GAAP EPS of -$2.92, revenue of $41.59M misses by $7.51M

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023 ...

As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Petosemtamab clinical update planned for first half of 2023 MCLA-129 clinical update planned for second...

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned fo...

Summary MRUS has traded with wide-reaching volatility over the course of the past 2 years. A series of setbacks on its pipeline conversions has seen a number of rapid selloffs, each resulting in tremendous drawdown. The latest headwind sprouts from the FDA requesting more enrollment...